Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR.

Cancer Cell. 2010 Nov 16;18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4.

2.

Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.

Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T, Couch FJ.

Gastroenterology. 2011 Apr;140(4):1303-1313.e1-3. doi: 10.1053/j.gastro.2010.12.039. Epub 2011 Jan 1.

3.

Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.

Feldmann G, Karikari C, dal Molin M, Duringer S, Volkmann P, Bartsch DK, Bisht S, Koorstra JB, Brossart P, Maitra A, Fendrich V.

Cancer Biol Ther. 2011 Jun 1;11(11):959-68. Epub 2011 Jun 1.

4.

Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.

Hermann PC, Sancho P, Cañamero M, Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L, Guerra C, Barbacid M, Wagner M, Vieira CR, Aicher A, Real FX, Sainz B Jr, Heeschen C.

Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12.

PMID:
25127677
5.

Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.

Qiu W, Sahin F, Iacobuzio-Donahue CA, Garcia-Carracedo D, Wang WM, Kuo CY, Chen D, Arking DE, Lowy AM, Hruban RH, Remotti HE, Su GH.

Oncotarget. 2011 Nov;2(11):862-73.

6.

Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.

Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.

PMID:
25683115
7.

A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.

Yamaguchi T, Ikehara S, Nakanishi H, Ikehara Y.

J Pathol. 2014 Oct;234(2):228-38. doi: 10.1002/path.4402. Epub 2014 Aug 4.

PMID:
25042889
8.

Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.

Qiu W, Tang SM, Lee S, Turk AT, Sireci AN, Qiu A, Rose C, Xie C, Kitajewski J, Wen HJ, Crawford HC, Sims PA, Hruban RH, Remotti HE, Su GH.

Gastroenterology. 2016 Jan;150(1):218-228.e12. doi: 10.1053/j.gastro.2015.09.013. Epub 2015 Sep 25.

9.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

10.

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.

Diersch S, Wirth M, Schneeweis C, Jörs S, Geisler F, Siveke JT, Rad R, Schmid RM, Saur D, Rustgi AK, Reichert M, Schneider G.

Oncogene. 2016 Jul 21;35(29):3880-6. doi: 10.1038/onc.2015.437. Epub 2015 Nov 23.

11.

Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.

Hattori H, Skoulidis F, Russell P, Venkitaraman AR.

Mol Cancer Ther. 2011 Apr;10(4):670-8. doi: 10.1158/1535-7163.MCT-10-0781. Epub 2011 Feb 2.

12.

Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.

Albury TM, Pandey V, Gitto SB, Dominguez L, Spinel LP, Talarchek J, Klein-Szanto AJ, Testa JR, Altomare DA.

Neoplasia. 2015 Feb;17(2):175-82. doi: 10.1016/j.neo.2014.12.006.

13.
14.

A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.

Inagawa Y, Yamada K, Yugawa T, Ohno S, Hiraoka N, Esaki M, Shibata T, Aoki K, Saya H, Kiyono T.

Carcinogenesis. 2014 Aug;35(8):1840-6. doi: 10.1093/carcin/bgu112. Epub 2014 May 24.

PMID:
24858378
15.

Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.

Endocr Relat Cancer. 2016 Oct;23(10):T57-67. doi: 10.1530/ERC-16-0269. Epub 2016 Aug 10. Review.

16.

NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.

Chen NM, Singh G, Koenig A, Liou GY, Storz P, Zhang JS, Regul L, Nagarajan S, Kühnemuth B, Johnsen SA, Hebrok M, Siveke J, Billadeau DD, Ellenrieder V, Hessmann E.

Gastroenterology. 2015 May;148(5):1024-1034.e9. doi: 10.1053/j.gastro.2015.01.033. Epub 2015 Jan 23.

17.

BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.

Shive HR, West RR, Embree LJ, Golden CD, Hickstein DD.

PLoS One. 2014 Jan 29;9(1):e87177. doi: 10.1371/journal.pone.0087177. eCollection 2014.

18.

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR, Sansom OJ.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51. doi: 10.1073/pnas.0908428107. Epub 2009 Dec 14.

19.

Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE.

Cancer Res. 1996 Dec 1;56(23):5360-4.

20.

Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions.

Carrière C, Gore AJ, Norris AM, Gunn JR, Young AL, Longnecker DS, Korc M.

Gastroenterology. 2011 Sep;141(3):1091-101. doi: 10.1053/j.gastro.2011.05.041. Epub 2011 May 27.

Supplemental Content

Support Center